A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
Open Access
- 1 February 1994
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 179 (2), 541-549
- https://doi.org/10.1084/jem.179.2.541
Abstract
From a human histocompatibility leukocyte antigen (HLA)-DR/DQ hemizygous, B lymphoblastoid progenitor, we isolated a cell line, 10.24.6, with a DR alpha missense mutation (96P-->96S), which results in an N-linked carbohydrate addition at position 94 in the DR alpha 2 domain. Several features of 10.24.6 cells suggest that the mutation disrupts normal intracellular formation of peptide/DR complexes. The mutant HLA-DR dimers, though expressed at the cell surface, lack the conformation of the mature, peptide-loaded class II molecules of the progenitor cell, as assessed by their loss of binding of certain antibodies and by the lack of stability in detergent (sodium dodecyl sulfate) solution. In addition, presentation of endocytosed antigen to HLA-DR-restricted T cells is defective in the mutant, but can be restored by transfection of a wild type DRA gene. Assays with synthetic peptides indicate that the 10.24.6 phenotype is not due to an intrinsic inability of the mutant DR molecules to bind peptides. Therefore, to directly evaluate peptide occupancy of the mutant molecules, we analyzed acid-eluted, HLA-DR-associated peptides. The predominant species from the 10.24.6 mutant is a nested set of invariant chain (Ii)-derived peptides that are undetectable in the DR eluate from progenitor cells. The region of DR alpha altered in the mutant molecules is thus implicated in normal formation of peptide/DR complexes. Further, the same set of Ii peptides associated with the DR molecules is present in the eluate from an antigen presentation mutant with a defect in an major histocompatibility complex (MHC)-linked gene. These results suggest that DR molecules in 10.24.6 and in certain presentation mutants are affected at the same or related steps in class II molecule biosynthesis, raising the possibility that class II molecules interact with an MHC-encoded accessory molecule during antigen presentation.Keywords
This publication has 38 references indexed in Scilit:
- Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.The Journal of Experimental Medicine, 1993
- Antigen presentation enhanced by the alternatively spliced invariant chain gene product p41Nature, 1992
- The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation.The Journal of Immunology, 1992
- MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8Nature, 1992
- Identification of a CD4 binding site on the β2 domain of HLA-DR moleculesNature, 1992
- The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptideCell, 1992
- Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA‐DRw17(DR3) moleculesEuropean Journal of Immunology, 1992
- A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex.The Journal of Experimental Medicine, 1991
- New class ll-like genes in the murine MHCNature, 1991
- Sequence analysis of peptides bound to MHC class II moleculesNature, 1991